EGRX Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced today that management will present at two investor conferences in June as follows:

             

Conference:

Jefferies 2017 Global Healthcare Conference

Date: Thursday, June 8, 2017
Time: 1:30 p.m. Eastern Daylight Time
Location: Grand Hyatt New York, NYC

Presenters:

Scott Tarriff, Chief Executive Officer, and David Pernock, President and Chief Commercial Officer

Webcast:

http://wsw.com/webcast/jeff105/egrx

             

Conference:

William Blair 37th Annual Growth Stock Conference

Date: Wednesday, June 14, 2017
Time: 1:20 p.m. Central Daylight Time
Location: Four Seasons Hotel, Chicago

Presenters:

David Pernock, President and Chief Commercial Officer, and David Riggs, Executive Vice President of Administration

Webcast:

http://wsw.com/webcast/blair53/egrx

 

The presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the company’s website at www.eagleus.com, under the Investors Section.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

EN
31/05/2017

Underlying

EGRXEagle Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

Eagle Pharmaceuticals Announces Divestiture of Barhemsys WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatme...

January 14, 2026 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Right...

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the...

October 30, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stoc...

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results ...

October 21, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quart...

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are available at . About Eagle Pharmaceuticals, Inc.Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in...

October 15, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarte...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at . About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meani...

October 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch